Ma 2019a.

Methods	Study design: Randomised clinical trial Study duration: April 2017 to February 2018 Duration of follow‐up: Not reported Setting: Hospital
Participants	Age (mean ± SD, range): TACE + RFA: 65.1 ± 5.9 years, 52‐77 years; TACE: 64.7 ± 5.8 years, 53‐76 years Male (n/total): TACE + RFA: 32/50; TACE alone: 34/50 Tumour diameter (mean ± SD, range): TACE + RFA: 4.1 ± 1.6 cm, 2‐7 cm; TACE alone：4.0 ± 1.3 cm, 2‐8 cm Child‐Pugh Class (patients): Class A: TACE + RFA: 29; TACE: 31 Class B: TACE + RFA: 21; TACE: 19
Interventions	TACE + RFA group (n = 50): TACE: Chemotherapeutic drugs: cisplatin 40‐80 mg, epirubicin 30‐50 mg, and theprubicin 20 mg RFA: CT‐guided RFA. RITA 1500 system TACE group (n = 50): Chemotherapeutic drugs: cisplatin 40‐80 mg, epirubicin 30‐50 mg, and theprubicin 20 mg
Outcomes	Tumour response, based on RECIST criteria Liver function Tumour diameter Adverse events
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.